Dovato vs Mavyret
A side-by-side look at two antiviral medications advertised on TV. Informational only — not medical advice.
| US Dovato | US Mavyret | |
|---|---|---|
| Generic name | dolutegravir/lamivudine | glecaprevir/pibrentasvir |
| Drug class | Two-Drug HIV Regimen (INSTI/NRTI) | Direct-Acting Antiviral Combination |
| Treats | HIV-1 infection | Hepatitis C |
| Category | Antiviral | Antiviral |
| Manufacturer | ViiV Healthcare | AbbVie |
| Year approved | 2019 | 2017 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $95M | $80M |
| Common side effects | Headache, Nausea, Diarrhea, Trouble sleeping | Headache, Fatigue, Nausea, Risk of hepatitis B reactivation |
Frequently asked questions
Is Dovato or Mavyret better?
Neither is universally "better." Dovato (dolutegravir/lamivudine) and Mavyret (glecaprevir/pibrentasvir) are both used for antiviral, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Dovato and Mavyret?
Dovato is a Two-Drug HIV Regimen (INSTI/NRTI) made by ViiV Healthcare, while Mavyret is a Direct-Acting Antiviral Combination made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Dovato has the larger estimated TV advertising budget of the two.